Output by NPO Biomed immunobiological products exceeded 6 million packages

| By | Drug Manufacturing, Microgen, Rostec

NPO Biomed, the largest developer and manufacturer of immunobiological products in the Perm Krai, an affiliate of NPO Microgen of Nacimbio Holding Company, part of Rostec Corporation, marked its 120th anniversary.

According to 2018 data, the annual output of various groups of immunobiological products manufactured at the Perm affiliate of NPO Microgen exceeded 6 million packages. In particular, the annual output of vaccines for prevention of diphtheria, tetanus, pertussis, hepatitis B, and other dangerous diseases has increased to about 23 million doses. Since 2015, the output of bacteriophage products for the treatment and prevention of infectious diseases has reached 1 million packages a year.

“Development and manufacturing of medicines to maintain health and create conditions for Russia’s independence from imports is one of the key objectives for our enterprises. Perm-based NPO Biomed employees efforts allowed to develop a number of medicinal products that can strongly compete with their foreign analogs. I am sure that the affiliate team will continue to make substantial contribution to the development of Russian immunobiological industry,” said Kirill Gaidash, General Director of NPO Microgen.

Currently, the company’s product portfolio includes more than 80 items.

SOURCE: gmpnews.ru
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.